Pay in 4 interest-free payments of $5.52 Learn more
Ships within 48 hours · Estimated delivery Sep 4 - Sep 9
Diarrhea rates run between 15-30% across the major GLP-1 trials
The data was then fitted to the Operational model
The Great (Oral) GLP-1 Scare Why the Stevanato narrative is flawed This is not something that should take you by surprise because Ive talked about it in the past, but Stevanatos stock has been weak lately (maybe an understatement): This has happened despite the company (imho) receiving incrementally positive news over the past few months
The pharma last month presented early-stage data for AZD6234 at the 2024 ObesityWeek of The Obesity Society, touting an encouraging safety profile and promising weight lossthough data around the candidate remain scant.
El equipo de expertos est aqu para ayudarle
US$ 29.69
US$ 28.21
US$ 21.95
US$ 20.75
